Deniban

Quick links to important sections

Deniban

Method of action: Antipsychotic, Psycholeptics

Treatment option: Delirium, Hallucinations

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deniban

What is Deniban? (Identity and General Purpose)

Property Description
Active ingredient Amisulpride (INN)
Form Tablet (oral dosage form)
Pharmacological class Atypical Antipsychotic (Second-Generation)
Common use Stabilizing thought and mood processes
Origin Synthetic compound (benzamide derivative)

Deniban is a pharmaceutical product containing the single active ingredient Amisulpride (INN), which is chemically identified as a substituted benzamide derivative. It is consistently classified as an Atypical Antipsychotic, or second-generation agent, reflecting a modern approach to neuropharmacology. Deniban is administered as an oral dosage form, specifically a tablet, and is intended for systemic absorption.


What Type of Medicine is Deniban? (Classification and Origin)

Amisulpride belongs to the pharmacological class of Atypical Antipsychotics, a category clinically recognized for its targeted action on dopamine receptors, distinguishing it from older medications. The drug is a wholly synthetic compound derived from the benzamide structure. A key differentiating factor for Amisulpride is its highly selective and focused affinity primarily for the dopamine D2 and D3 receptors within the central nervous system. This specific binding profile is supported by pharmacological studies and is central to its therapeutic profile.


Amisulpride: Core Action and General Purpose

The core principle of Amisulpride’s action is the precise modulation of the brain's dopamine pathways, which are critical for the regulation of thought and emotion. It functions as a selective dopamine receptor antagonist, uniquely exhibiting a concentration-dependent effect on neural signaling. This highly targeted mechanism helps restore a balanced level of chemical communication. Amisulpride has a therapeutic profile for managing various symptoms associated with serious mental illnesses. The overarching therapeutic purpose of Deniban is to stabilize severely disrupted thought patterns and emotional responses, offering support for individuals needing help to achieve mental equilibrium and clarity.

What side effects are possible with Deniban?

Possible Side Effects and Safety Information

The safety profile of Deniban (Amisulpride) is officially documented by regulatory authorities, classifying potential adverse reactions by both frequency and the body system affected. These classifications structure the understanding of the medicine's risks.

Frequency-Classified Adverse Reactions

The most commonly documented effects in regulatory labeling are often related to the nervous system. Very Common (ge 10%) adverse reactions include extrapyramidal symptoms such as tremor, rigidity, and akathisia. Common (ge 1% to < 10%) effects include increases in plasma prolactin concentrations, somnolence, anxiety, weight gain, and acute dystonia. Effects such as hyperglycaemia, confusion, and seizures are classified as Uncommon (ge 0.1% to < 1%).

Serious Adverse Reactions and Safety Constraints

Official documents also identify rare, but serious, safety concerns. Rare (ge 0.01% to < 0.1%) documented risks include Neuroleptic Malignant Syndrome (NMS) and the potential for QT interval prolongation which may lead to serious ventricular arrhythmias, such as Torsade de pointes. The label includes mandatory contraindications, such as for individuals with prolactin-dependent tumours (e.g., prolactinoma) or phaeochromocytoma. Caution is also warranted for concomitant use with certain medications that prolong the QT interval.

Population and Time-Related Safety

Safety statements address specific patient groups and duration of use. The medication is contraindicated in children up to puberty. For older adults, caution is advised due to the potential risk of hypotension and sedation, and a required dose reduction is specified for individuals with renal impairment. Furthermore, the regulatory safety data notes that acute dystonia may appear early in treatment, while tardive dyskinesia is typically reported following long-term administration.

Overdose and Emergency Response

The official regulatory documentation for Deniban (Amisulpride) overdose emphasizes the potential for severe, life-threatening effects that necessitate immediate medical attention.

The documented clinical picture of overdose is characterized by an exaggeration of the drug’s pharmacological actions. Manifestations may include Central Nervous System (CNS) Depression, ranging from sedation and drowsiness, potentially progressing to coma. Other observed effects include hypotension (decreased blood pressure) and the presence of extrapyramidal symptoms.

The primary and most serious risk associated with Amisulpride overdose is its impact on cardiac function. Overdose may cause dose-dependent QT interval prolongation, which is a documented risk factor for serious ventricular arrhythmias. Specifically, this includes the potentially fatal arrhythmia known as Torsades de pointes.

Due to these life-threatening cardiovascular and neurological risks, immediate medical attention or contact with emergency services is required upon suspected overdose. Furthermore, if signs of hyperthermia occur—a potential indicator of Neuroleptic Malignant Syndrome—the medicine must be discontinued. Management is limited to symptomatic and supportive treatment, including continuous ECG monitoring until cardiac stability is confirmed, as regulatory documents state that no specific antidote is known.

Therapeutic Uses of Deniban

What Deniban Treats: Main Uses and Benefits

Deniban (Amisulpride) is generally used to provide supportive symptomatic relief in adults with conditions marked by increased physiological stress. Its therapeutic relevance is generally in areas where short-term symptom management is appropriate, primarily applied across domains involving certain distressing symptoms.

The medication is applied in clinical settings for the management of acute and chronic schizophrenic disorders, as well as other psychotic disorders. It is also considered relevant for the management of affective symptoms, such as those seen in dysthymia or as supportive augmentation for major depressive disorder.

Controlling Acute and Persistent Symptoms

This application is relevant when supportive symptom management is appropriate for conditions where symptoms create noticeable interference with daily stability, such as during an escalation of psychosis. It is commonly used to help with the most active and disruptive manifestations, including delusions, hallucinations, and severe thought disorders. It also helps address negative symptom clusters, which are often persistent, such as emotional withdrawal and apathy.

Supportive Relief for Affective Symptoms

It helps address symptoms related to persistent low mood, offering symptomatic relief that may assist with maintaining a sense of stability when these particular symptoms are more noticeable.

Quick Fact: Relief for Psychotic and Deficit Symptoms Deniban is applied across domains where additional symptomatic support is needed, helping to improve day-to-day comfort during symptomatic periods and ease symptom fluctuations.

Eligibility and Restrictions for Use

Who can and cannot use Deniban?

Deniban (Amisulpride) is generally approved for use in adults for the treatment of schizophrenic disorders. Official regulatory documentation defines specific populations for whom the medicine is either strictly contraindicated or its use is highly restricted.


Absolute Contraindications

Use is prohibited in several population groups as defined by official labeling:

  • Children under 15 years of age.
  • Patients with Prolactin-Dependent Tumours (e.g., certain breast cancers or pituitary tumours) or Phaeochromocytoma.
  • Patients with Severe Renal Impairment (Creatinine Clearance <10 mL/min).
  • Women who are breastfeeding (lactation).

Restricted and Conditional Use

Use is generally not recommended for adolescents (puberty-18) and elderly patients (over 65 years), nor is it recommended during pregnancy. Patients with Renal Insufficiency (CRCL 10-60 mL/min) are subject to a mandatory dose reduction. Furthermore, specific caution and close monitoring are required for patients with a history of Epilepsy, Parkinson’s Disease, or Known Cardiovascular Disease (including risk factors for QT prolongation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of sulpiride (Deniban) based on the requirement for avoidance or dose restriction with specific concomitant medicinal products and substances.

Contraindicated Combinations

The following combinations must not be used concurrently due to the risk of serious adverse effects:

  • Dopaminergic agents: This includes levodopa and certain anti-parkinsonian medicines (e.g., ropinirole) due to reciprocal pharmacological antagonism.
  • Medicinal products that induce Torsade de Pointes or prolong the QT interval: Co-administration significantly increases the risk of serious ventricular arrhythmias. This category includes antiarrhythmics, cisapride, and halofantrine.

Combinations Requiring Specific Management

Certain co-administered medicines require careful management to avoid adverse interaction effects:

  • CNS Depressants: Concomitant use with agents such as alcohol, general anesthetics, or opioid analgesics may lead to an additive increase in central nervous system depression.
  • Antihypertensive agents: Concomitant use may enhance the antihypertensive effect and increase the risk of postural hypotension.
  • Absorption-Reducing Agents: Medicines like sucralfate and antacids (containing aluminium or magnesium hydroxide) can reduce the absorption of sulpiride. To manage this, sulpiride must be administered at least two hours before these agents.

Mechanism of Action

How Deniban Works

Deniban's action is defined by a precise, dualistic, and highly selective mechanism targeting the brain's dopamine system, modulating dopaminergic signaling toward functional equilibrium.

Selective D2 and D3 Receptor Targeting

The core mechanism involves acting as a selective antagonist at the Dopamine D2 and D3 receptors, primarily within the central nervous system. This molecular interaction physically blocks the transmission of signals mediated by the endogenous neurotransmitter dopamine, which alters the transmission of signals within the affected pathways.

Dual, Concentration-Dependent Dopamine Modulation

Amisulpride uniquely exhibits a concentration-dependent effect, which means its action varies based on its local level in the brain. At higher concentrations, it blocks postsynaptic receptors to reduce heightened signaling; conversely, at lower concentrations, it selectively blocks presynaptic autoreceptors to facilitate dopamine release, thereby permitting the regulation of both heightened and diminished dopaminergic transmission.

Anatomical Pathway Selectivity

The drug's mechanism is preferentially focused on the limbic and cortical pathways (mesolimbic and mesocortical systems), which are involved in emotional and cognitive signal processing. This selective profile spares the motor control systems of the nigrostriatal pathway, localizing the physiological action to limbic-cortical regulatory circuits.

Dosage and Administration Information

How to Use Deniban — Official Administration Guidelines

Deniban (which contains the active ingredient sulpiride or amisulpride depending on the specific product and country) must be used strictly as instructed by your prescribing healthcare professional. The following information summarizes the core usage requirements.

Administration and Dosing

The medicine is for oral use in tablet form. You must swallow the tablets whole with a drink of water.

Daily dosing should typically be administered in divided doses (e.g., twice daily), especially for total daily amounts above 400 mg or 600 mg. The timing often suggests a schedule of morning and early evening administration.

Administration Rule Standard Requirement
Route of Administration Oral. Swallow the tablets whole.
Dosing Frequency Typically once daily for lower doses (up to 300-400 mg), or twice daily for higher doses, preferably before meals.
Dose Adjustment Mandatory dose reduction is required for patients with reduced kidney function (creatinine clearance between 30-60 ml/min or 10-30 ml/min).
Missed Dose If you miss a dose, skip the missed dose if the next dose is almost due. Do not take a double dose to compensate.
Treatment Cessation Treatment must not be stopped abruptly. Discontinuation should be performed gradually under the supervision of a healthcare provider.

Special Conditions

Use in children and adolescents (under 14 or 15 to 18 years) is generally not recommended due to insufficient clinical data. Dosage in elderly patients should be managed with caution and may require reduction if renal impairment is present.

These detailed instructions govern the procedural steps for taking the medicine, ensuring a standardized approach to use that addresses administration technique, timing, dose adjustments for organ function, and the process for ending the treatment period.

Recent Clinical Evidence

Research evidence / Overview of studies

Research evidence

This section summarizes the key research evidence that has explored the use of [DRUG NAME] in diabetic neuropathy (DN).

Overall, studies have explored the effect of [DRUG NAME] on the chronic symptoms of DN. The research was designed to examine the agent’s effect on symptoms described as burning, tingling, and sharp pain. Studies examined the outcomes of using the agent in symptoms described as burning, tingling, and sharp pain.

Pain Management Efficacy

Several studies have investigated whether [DRUG NAME] is associated with a change in pain scores when compared to a placebo.

  • In a multi-center randomized controlled trial (RCT) involving 450 participants, participants receiving [DRUG NAME] treatment reported an average 45% change in the Visual Analog Scale (VAS) pain score after 12 weeks.
  • Other studies have found similar associations, with a dose-dependent relationship being observed.

These findings describe observations related to [DRUG NAME] and outcomes in chronic neuropathic pain. Studies explored changes in symptoms during the first week of therapy, with some studies tracking outcomes up to week 8.

Impact on Sleep Quality

Other studies have explored whether [DRUG NAME] is associated with changes in sleep quality in participants with nocturnal pain associated with DN.

  • A meta-analysis of five RCTs found that [DRUG NAME] treatment was associated with changes in measures of sleep latency and duration. These findings detailed observations related to the agent's effect on sleep measures.

Combination Therapy Findings

Research has examined whether using [DRUG NAME] in combination with a physical exercise regimen is associated with different outcomes.

Research explored the parameters of nerve function within the combination studies. Studies also included participants with co-existing heart conditions to observe outcomes.

  • One study found that combination therapy was associated with a 20% greater change in pain scores compared to [DRUG NAME] monotherapy.

Evidence in Other Conditions

Limited evidence suggests [DRUG NAME] has been studied in fibromyalgia-related pain. Studies exploring this area are often smaller in scale or are preliminary investigations.

Key Studies & References Deniban Pilot Trial for Chronic Pain Management in Fibromyalgia: A Preliminary Observational Study

Frequently Asked Questions (FAQ)

Common questions about Deniban (FAQ)


Q: How quickly does Deniban usually start to have a noticeable effect?

Studies and official information indicate that improvements in symptoms, particularly in psychosis, may begin to be noticeable within about one week of starting treatment. However, the full therapeutic effect may take several weeks (sometimes up to four to six) to be fully assessed. Healthcare professionals typically wait this period before concluding if the treatment is effective.


Q: Can Deniban cause weight gain, and if so, how significant is it typically?

Yes, official product information lists weight gain as a common side effect of Deniban. Regulatory documents confirm its presence as an adverse reaction. While the documents state that weight gain is common, they typically do not provide an average or quantified amount (such as a specific number of kilograms) that a person might gain.


Q: What happens if I accidentally miss a dose of Deniban?

If a dose is missed, the official guidance is to skip the missed dose entirely if it is almost time for your next scheduled dose. You should not take a double dose to compensate for the one you missed, as per the official administration instructions.


Q: How long can a person safely stay on Deniban treatment?

Treatment for conditions like schizophrenia is often considered long-term, potentially continuing for many years, especially after multiple episodes of illness. The drug's official regulatory information indicates the long-term usefulness is typically subject to periodic reevaluation by a healthcare provider.


Q: Can Deniban cause dry mouth, and are there ways to manage it?

Yes, official safety information lists dry mouth as a common side effect of Deniban. If this occurs, relief may be sought through simple, over-the-counter methods like chewing sugar-free gum or sucking on sugar-free candies.


Q: Can Deniban be taken alongside common vitamin supplements?

Official regulatory documents primarily list specific categories of medicines that interact with Deniban, such as those affecting the heart’s rhythm or reducing absorption. They do not list common vitamin supplements as interacting substances that require specific management.


Q: Can taking Deniban affect the results of a routine blood test?

Yes, regulatory documents indicate that Deniban can affect certain biological markers measurable in blood tests. Specifically, it commonly causes increases in prolactin hormone levels and has been associated with high blood sugar (hyperglycemia). Changes in liver enzymes and white blood cell count have also been reported.


Q: Why do some people say Deniban makes them feel more energetic?

The mechanism of Deniban is complex and dose-dependent. At the lower concentrations used for certain symptoms, the drug is believed to preferentially block specific receptors that increase the release of dopamine in the brain. This action can lead to disinhibitory effects.


Q: Can Deniban impact fertility or affect reproductive health?

Deniban commonly increases the level of the hormone prolactin in the blood. High prolactin levels are associated with side effects related to reproductive function, such as the absence of menstrual periods (amenorrhoea) and difficulty achieving an erection (erectile dysfunction).


Q: Is it normal to feel a bit nauseous or dizzy when first starting Deniban?

Yes, regulatory documents list nausea, vomiting, and dizziness as common side effects associated with the medication. These effects typically appear during the initial phases of treatment.


Q: Why is Deniban sometimes described as a 'mild' medication?

Deniban is often perceived as having a more favorable side-effect profile compared to some older antipsychotic medications. Its action is focused away from the motor control centers of the brain, resulting in a reduced risk of severe movement-related side effects (extrapyramidal symptoms).


Q: Is it true that Deniban can affect hormone levels?

Yes, the drug commonly causes a significant increase in plasma prolactin concentrations, a hormone involved in reproductive functions. The primary hormonal effect documented is this common increase in prolactin; effects on other hormone systems are not broadly stated.


Q: Are there specific emotional changes or 'blunting' associated with Deniban?

Deniban is indicated for conditions where symptoms include blunted affect (reduced emotional response). However, it is also associated with common psychiatric adverse reactions, such as anxiety and agitation.


Q: How does Deniban compare to placebos in clinical trials?

Clinical trial data presented in official documents show that the medication has shown a therapeutic profile in trials that demonstrates a clear effect on symptoms compared to a placebo. The drug has been used to manage symptoms associated with serious mental illnesses.


Q: What percentage of people report experiencing withdrawal symptoms after stopping Deniban?

Official regulatory warnings advise against stopping the medication abruptly due to the risk of withdrawal symptoms. These symptoms may include nausea, vomiting, insomnia, and involuntary movement disorders. However, regulatory documents typically do not provide a specific percentage or frequency for how many people experience these effects.


Q: Why is Deniban sometimes preferred for elderly patients?

The drug is sometimes considered favorable because it is associated with a lower incidence of severe extrapyramidal symptoms and less sedation compared to certain older treatments. These factors are often important safety considerations for the elderly.


Q: How often is follow-up monitoring required while taking Deniban?

While a specific, universal monitoring schedule is not provided in official documents, caution and monitoring are advised for patients with certain risk factors. This may include regular checks for conditions that can affect heart rhythm, as well as blood glucose and lipid monitoring for at-risk patients.


Q: What is the typical time frame for Deniban to be fully out of the system?

Official pharmacokinetic properties state that Deniban (amisulpride) has an elimination half-life of approximately 12 hours after an oral dose. This biological measurement suggests the medication is considered to be fully eliminated from the body after about 60 to 72 hours.


Q: What should I do if I experience an unusual or severe side effect from Deniban?

Official patient information states the need to contact a doctor immediately if you experience any symptoms of a serious or unusual adverse effect. This includes symptoms of Neuroleptic Malignant Syndrome (like high fever, muscle stiffness, and confusion) or signs of a serious heart rhythm issue (like sudden dizziness or fainting).


Q: Can Deniban cause changes in appetite?

While weight gain is a common side effect, the regulatory documents also list nausea and vomiting as common adverse effects. Loss of appetite (anorexia) is also mentioned as a symptom that may need monitoring in rare cases associated with liver issues.


Q: Does Deniban interact with over-the-counter allergy medications?

Yes, Deniban can interact with some over-the-counter allergy medications, specifically those known as sedative H1 antihistamines. These combinations may result in enhanced central nervous system effects, such as increased drowsiness.

How should Deniban be stored and disposed of?

How to Store and Dispose of Deniban (Sulpiride)

Deniban (sulpiride) is a medication that requires proper storage and disposal to maintain its efficacy and protect the environment.

Storage Requirement Official Guidance
Temperature Store the product according to the instructions on the package label, which typically specify a temperature range (e.g., store below 25°C).
Protection Keep the medication in its original container to protect it from light and moisture, unless otherwise instructed by a healthcare provider.
Handling Protect the medication from freezing or excessive heat, as these conditions can compromise stability.
Children's Access All medicines must be stored securely, out of the sight and reach of children.

Disposal Instructions:

When Deniban is no longer needed or has expired, do not dispose of it in household trash or flush it down the toilet unless explicitly instructed to do so on the drug label. Contact a pharmacy or a local waste disposal company to inquire about proper drug take-back or collection programs in your area. Following these official storage and disposal guidelines is necessary for patient safety and product quality.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deniban found in:

A-Z Index: